Legend Biotech Corporation

Legend Biotech Corporation reported total revenue of $1.03 billion for fiscal year 2025, driven primarily by collaboration revenue of $944.8 million and license and other revenue of $84.1 million. The company recorded an operating loss of $136.5 million and a net loss of $296.8 million, resulting in a total comprehensive loss of $106.4 million. Basic and diluted loss per share were both -$1. The company maintained a strong liquidity position with cash and cash equivalents of $901.9 million and total assets of $1.73 billion. Net cash used in operating activities was $100.2 million, while investing activities generated $709.6 million primarily from time deposit movements. The company's equity stood at $1.00 billion with total liabilities of $731.6 million.

Key Takeaways